Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) EBIT Margin: 2022-2025

Historic EBIT Margin for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to -30.85%.

  • Phathom Pharmaceuticals' EBIT Margin rose 40210.00% to -30.85% in Q3 2025 from the same period last year, while for Sep 2025 it was -145.03%, marking a year-over-year increase of 95099.00%. This contributed to the annual value of -502.18% for FY2024, which is 2403037.00% up from last year.
  • As of Q3 2025, Phathom Pharmaceuticals' EBIT Margin stood at -30.85%, which was up 79.66% from -151.69% recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' EBIT Margin registered a high of 1,373.90% during Q1 2022, and its lowest value of -10,245.60% during Q4 2023.
  • For the 3-year period, Phathom Pharmaceuticals' EBIT Margin averaged around -1,367.56%, with its median value being -200.30% (2024).
  • Its EBIT Margin has fluctuated over the past 5 years, first plummeted by 1,073,135bps in 2023, then surged by 1,004,530bps in 2024.
  • Over the past 4 years, Phathom Pharmaceuticals' EBIT Margin (Quarterly) stood at 485.75% in 2022, then plummeted by 1,073,135bps to -10,245.60% in 2023, then spiked by 1,004,530bps to -200.30% in 2024, then skyrocketed by 40,210bps to -30.85% in 2025.
  • Its last three reported values are -30.85% in Q3 2025, -151.69% for Q2 2025, and -276.53% during Q1 2025.